News
PHIO
0.7500
+2.66%
0.0194
Phio Pharmaceuticals Granted US Patent #11396654 For "NEUTRAL NANOTRANSPORTERS" for "cancer, autoimmune diseases, inflammatory diseases, viral diseases, HIV, Hepatitis C, flu and cardiovascular diseases."
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=11396654&OS=11396654&RS=1
Benzinga · 07/26 14:56
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Is About To Turn The Corner
Phio Pharmaceuticals Corp. ( NASDAQ:PHIO ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 07/11 10:53
BRIEF-Phio Pharmaceuticals Presents Study Outline Of Its First Clinical Trial With Ph-762 For Advanced Melanoma At The 2022 Asco Annual Meeting
reuters.com · 06/06 18:16
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented a trial-in-progress poster descr...
PR Newswire · 06/06 18:15
Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells
Benzinga · 05/16 16:22
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/16 12:16
BRIEF-Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity Of HER2-CAR-T Cells At Asgct 2022
reuters.com · 05/16 12:05
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new preclinical data showing tha...
PR Newswire · 05/16 12:00
BRIEF-Phio Pharmaceuticals Reports Q1 2022 Results And Provides Business Update
reuters.com · 05/12 21:23
Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.11
Phio Pharmaceuticals press release (NASDAQ:PHIO): Q1 GAAP EPS of -$0.19 beats by $0.11. At March 31, 2022, the Company had cash of $20.5 million as compared with $24.1 million at
Seekingalpha · 05/12 20:52
BRIEF-Phio Pharmaceuticals - Announced Departure Of Gerrit Dispersyn From His Role As President And CEO
reuters.com · 05/05 12:36
Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, announced today that it will present a trial-in-...
PR Newswire · 05/03 11:30
Phio Pharmaceuticals Announces Upcoming Presentation Of PH-894 Data At ASGCT 25th Annual Meeting 2022
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,
Benzinga · 05/02 20:49
BRIEF-Phio Pharmaceuticals Corp - Effective As Of April 27, Increased Size Of Board To Eight Members
reuters.com · 05/02 11:56
BRIEF-Phio Pharmaceuticals Announces The Appointment Of Patricia A. Bradford To Its Board Of Directors
reuters.com · 05/02 11:55
Phio begins enrollment in phase 1b trial of PH-762 to treat skin cancer
Phio Pharmaceuticals (NASDAQ:PHIO) said it opened patient enrollment in a phase 1b trial of PH-762 to treat advanced melanoma, a type of skin cancer. "We are excited to advance our
Seekingalpha · 04/26 18:24
Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.
Benzinga · 04/26 15:12
Phio Pharma Reports Commencement Of Its Phase 1b Trial Of PH-762 For Treatment Of Advanced Melanoma
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,
Benzinga · 04/26 14:15
Phio Pharmaceuticals Opens Patient Enrollment in Phase 1b Trial of Skin Cancer Treatment
MT Newswires · 04/26 11:20
22 Stocks Moving in Friday's Pre-Market Session
Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and SNDBX reported a strategic partnership for gaming and e-Sports.
Benzinga · 04/22 09:56
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL-based therapeutics are used to strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT) and directly modify cells in the tumor microenvironment (the TME) to weaken a tumors defense. Its lead product candidate is PH-762, which is an INTASYL compound that activates immune cells to better recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1, a clinically validated target for immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression that impacts cell differentiation, and hence, cell function. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.